Aflibercept is a vascular epidermal growth factor (VEGF-A and PlGF) receptor inhibitor that inhibits the growth of neovascularization. It can be used to study a variety of diseases caused by ocular neovascularization.
AFN-1252 (API-1252; Debio-1452) is an enoyl-(acyl-carrier protein) reductase fabl inhibitor. AFN-1252 exhibits typical MIC90 values of ⩽0.015 μg/ml against diverse clinical isolates of S. aureus.
AFN-1252 (API-1252; Debio-1452) is an enoyl-(acyl-carrier protein) reductase fabl inhibitor. AFN-1252 exhibits typical MIC90 values of ⩽0.015 μg/ml against diverse clinical isolates of S. aureus.
AFN-1252 (API-1252; Debio-1452) is an enoyl-(acyl-carrier protein) reductase fabl inhibitor. AFN-1252 exhibits typical MIC90 values of ⩽0.015 μg/ml against diverse clinical isolates of S. aureus.
Afobazole (CM346) produces anxiolytic and neuroprotective effects without any sedative or muscle relaxant actions.
Afobazole (CM346) produces anxiolytic and neuroprotective effects without any sedative or muscle relaxant actions.
Afuresertib (GSK2110183; LAE002) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively.
Afuresertib (GSK2110183; LAE002) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively.
Afuresertib (GSK2110183; LAE002) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively.